Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL. RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL to RANK, a cellular receptor of RAN...

Full description

Bibliographic Details
Main Authors: Yuki Ozaki, Masanori Koide, Yuriko Furuya, Tadashi Ninomiya, Hisataka Yasuda, Midori Nakamura, Yasuhiro Kobayashi, Naoyuki Takahashi, Nobuo Yoshinari, Nobuyuki Udagawa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5609750?pdf=render

Internet

http://europepmc.org/articles/PMC5609750?pdf=render

Similar Items